PHRIXUS PHARMACEUTICALS, INC.

Basic Information

1600 HURON PARKWAY BLDG. 520, 2ND FLOOR
ANN ARBOR, MI, 48109-5001

Company Profile

n/a

Additional Details

Field Value
DUNS: 620122676
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 2


  1. Treatment of Muscular Dystrophy-associated Dilated Cardiomyopathy with P-188

    Amount: $622,877.00

    DESCRIPTION (provided by applicant): The long-term goal of this project is to obtain FDA approval to market Poloxamer-188 (P- 188) for the prevention and treatment of dilated cardiomyopathy (DCM) and ...

    SBIR Phase I 2012 Department of Health and Human Services
  2. Effects of P-188 on Respiratory Function and Diaphragm Degeneration in the mdx mo

    Amount: $583,225.00

    DESCRIPTION (provided by applicant): The long-term goal of this project is to develop Poloxamer-188 (P-188) for the delay or prevention of respiratory deficits in patients with Duchenne muscular dystr ...

    SBIR Phase I 2011 Department of Health and Human Services
  3. Poloxamer 188 mechanism of action in ischemic heart failure.

    Amount: $306,708.00

    DESCRIPTION (provided by applicant): This project was initiated to determine how Poloxamer-188 (P-188) improves cardiac function in ischemic heart failure (HF). While it is accepted that lack of oxyge ...

    STTR Phase I 2010 Department of Health and Human Services
  4. Development of Poloxamer-188 for the Treatment of Muscular Dystrophy Associated H

    Amount: $379,487.00

    DESCRIPTION (provided by applicant): This application focuses on initial preclinical steps required to develop Poloxamer-188 (P-188) for the treatment of heart failure (HF) associated with Duchene and ...

    SBIR Phase I 2009 Department of Health and Human Services
  5. Poloxamer-188 for the prevention of fibrosis during peritoneal dialysis

    Amount: $277,646.00

    DESCRIPTION (provided by applicant): Project Summary. This application is focused on preventing adverse events associated with chronic peritoneal dialysis (PD), a renal replacement the ...

    SBIR Phase I 2008 Department of Health and Human Services
  6. Chronic Treatment of Heart Failure With Poloxamer-188

    Amount: $215,084.00

    DESCRIPTION (provided by applicant): Heart failure (HF) is a major medical problem in the United States affecting more than 5 million patients. It is expected to impact 11 million patients by 2011. Of ...

    SBIR Phase I 2007 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government